|
1
|
Greenlee RT, Murray T, Bolden S and Wingo
PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000.
View Article : Google Scholar
|
|
2
|
Ushijima K: Current status of gynecologic
cancer in Japan. J Gynecol Oncol. 20:67–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soonthornthum T, Arias-Pulido H, Joste N,
et al: Epidermal growth factor receptor as a biomarker for cervical
cancer. Ann Oncol. 22:2166–2178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Noordhuis MG, Eijsink JJ, Ten Hoor KA, et
al: Expression of epidermal growth factor receptor (EGFR) and
activated EGFR predict poor response to (chemo)radiation and
survival in cervical cancer. Clin Cancer Res. 15:7389–7397. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gadducci A, Guerrieri ME and Greco C:
Tissue biomarkers as prognostic variables of cervical cancer. Crit
Rev Oncol Hematol. 86:104–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Noordhuis MG, Eijsink JJ, Roossink F, et
al: Prognostic cell biological markers in cervical cancer patients
primarily treated with (chemo)radiation: a systematic review. Int J
Radiat Oncol Biol Phys. 79:325–334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sanbhnani S and Yeong FM: CHFR: a key
checkpoint component implicated in a wide range of cancers. Cell
Mol Life Sci. 69:1669–1687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banno K, Yanokura M, Kawaguchi M, et al:
Epigenetic inactivation of the CHFR gene in cervical cancer
contributes to sensitivity to taxanes. Int J Oncol. 31:713–720.
2007.PubMed/NCBI
|
|
9
|
Thigpen JT, Blessing JA, Fowler WC Jr and
Hatch K: Phase II trials of cisplatin and piperazinedione as single
agents in the treatment of advanced or recurrent non-squamous cell
carcinoma of the cervix: a Gynecologic Oncology Group Study. Cancer
Treat Rep. 70:1097–1100. 1986.PubMed/NCBI
|
|
10
|
Papadimitriou CA, Sarris K, Moulopoulos
LA, et al: Phase II trial of paclitaxel and cisplatin in metastatic
and recurrent carcinoma of the uterine cervix. J Clin Oncol.
17:761–766. 1999.PubMed/NCBI
|
|
11
|
Zhang Y, Chen FQ, Sun YH, Zhou SY, Li TY
and Chen R: Effects of DNMT1 silencing on malignant phenotype and
methylated gene expression in cervical cancer cells. J Exp Clin
Cancer Res. 30:982011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng DF, Kanai Y, Sawada M, et al: DNA
methylation of multiple tumor-related genes in association with
overexpression of DNA methyltransferase 1 (DNMT1) during multistage
carcinogenesis of the pancreas. Carcinogenesis. 27:1160–1168. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu N, Zhao LJ, Li XP, Wang JL, Chai GL
and Wei LH: Histone deacetylase inhibitors inducing human cervical
cancer cell apoptosis by decreasing DNA-methyltransferase 3B. Chin
Med J (Engl). 125:3273–3278. 2012.PubMed/NCBI
|
|
14
|
Tadokoro T, Rybanska-Spaeder I, Kulikowicz
T, et al: Functional deficit associated with a missense Werner
syndrome mutation. DNA Repair (Amst). 12:414–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masuda K, Banno K, Yanokura M, et al:
Association of epigenetic inactivation of the WRN gene with
anticancer drug sensitivity in cervical cancer cells. Oncol Rep.
28:1146–1152. 2012.PubMed/NCBI
|
|
16
|
Futami K, Takagi M, Shimamoto A, Sugimoto
M and Furuichi Y: Increased chemotherapeutic activity of
camptothecin in cancer cells by siRNA-induced silencing of WRN
helicase. Biol Pharm Bull. 30:1958–1961. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agrelo R, Cheng WH, Setien F, et al:
Epigenetic inactivation of the premature aging Werner syndrome gene
in human cancer. Proc Natl Acad Sci USA. 103:8822–8827. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Höpfl G, Ogunshola O and Gassmann M: HIFs
and tumors - causes and consequences. Am J Physiol Regul Integr
Comp Physiol. 286:R608–R623. 2004.PubMed/NCBI
|
|
19
|
Liao D and Johnson RS: Hypoxia: a key
regulator of angiogenesis in cancer. Cancer Metastasis Rev.
26:281–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vaupel P: Tumor microenvironmental
physiology and its implications for radiation oncology. Semin
Radiat Oncol. 14:198–206. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Michieli P: Hypoxia, angiogenesis and
cancer therapy: to breathe or not to breathe? Cell Cycle.
8:3291–3296. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sasabe E, Zhou X, Li D, Oku N, Yamamoto T
and Osaki T: The involvement of hypoxia-inducible factor-1alpha in
the susceptibility to gamma-rays and chemotherapeutic drugs of oral
squamous cell carcinoma cells. Int J Cancer. 120:268–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Smith-McCune KK and Weidner N:
Demonstration and characterization of the angiogenic properties of
cervical dysplasia. Cancer Res. 54:800–804. 1994.PubMed/NCBI
|
|
24
|
Mazibrada J, Rittà M, Mondini M, et al:
Interaction between inflammation and angiogenesis during different
stages of cervical carcinogenesis. Gynecol Oncol. 108:112–120.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee WY, Huang SC, Hsu KF, Tzeng CC and
Shen WL: Roles for hypoxia-regulated genes during cervical
carcinogenesis: somatic evolution during the
hypoxia-glycolysis-acidosis sequence. Gynecol Oncol. 108:377–384.
2008. View Article : Google Scholar
|
|
26
|
Hutchison GJ, Valentine HR, Loncaster JA,
et al: Hypoxia-inducible factor 1alpha expression as an intrinsic
marker of hypoxia: correlation with tumor oxygen, pimonidazole
measurements, and outcome in locally advanced carcinoma of the
cervix. Clin Cancer Res. 10:8405–8412. 2004. View Article : Google Scholar
|
|
27
|
Burri P, Djonov V, Aebersold DM, et al:
Significant correlation of hypoxia-inducible factor-1alpha with
treatment outcome in cervical cancer treated with radical
radiotherapy. Int J Radiat Oncol Biol Phys. 56:494–501. 2003.
View Article : Google Scholar
|
|
28
|
Bachtiary B, Schindl M, Pötter R, et al:
Overexpression of hypoxia-inducible factor 1alpha indicates
diminished response to radiotherapy and unfavorable prognosis in
patients receiving radical radiotherapy for cervical cancer. Clin
Cancer Res. 9:2234–2240. 2003.
|
|
29
|
Bai H, Ge S, Lu J, Qian G and Xu R:
Hypoxia inducible factor-1α-mediated activation of survivin in
cervical cancer cells. J Obstet Gynaecol Res. 39:555–563. 2013.
|
|
30
|
Li R, Zhou L and Liu Q: Effect of
different animal skin on the transdermal speed constant of
sinomenine. Zhong Yao Cai. 21:580–583. 1998.(In Chinese).
|
|
31
|
Luczak MW, Roszak A, Pawlik P, et al:
Transcriptional analysis of CXCR4, DNMT3A, DNMT3B and DNMT1 gene
expression in primary advanced uterine cervical carcinoma. Int J
Oncol. 40:860–866. 2012.PubMed/NCBI
|
|
32
|
Kummar S, Raffeld M, Juwara L, et al:
Multihistology, target-driven pilot trial of oral topotecan as an
inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
Clin Cancer Res. 17:5123–5131. 2011.PubMed/NCBI
|
|
33
|
Rapisarda A, Shoemaker RH and Melillo G:
Targeting topoisomerase I to inhibit hypoxia inducible factor 1.
Cell Cycle. 3:172–175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rapisarda A, Uranchimeg B, Scudiero DA, et
al: Identification of small molecule inhibitors of
hypoxia-inducible factor 1 transcriptional activation pathway.
Cancer Res. 62:4316–4324. 2002.PubMed/NCBI
|
|
35
|
Rapisarda A, Uranchimeg B, Sordet O,
Pommier Y, Shoemaker RH and Melillo G: Topoisomerase I-mediated
inhibition of hypoxia-inducible factor 1: mechanism and therapeutic
implications. Cancer Res. 64:1475–1482. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang K, Ang KK, Milas L, Hunter N and Fan
Z: The epidermal growth factor receptor mediates radioresistance.
Int J Radiat Oncol Biol Phys. 57:246–254. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Milas L, Fan Z, Andratschke NH and Ang KK:
Epidermal growth factor receptor and tumor response to radiation:
in vivo preclinical studies. Int J Radiat Oncol Biol Phys.
58:966–971. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Halle C, Lando M, Svendsrud DH, et al:
Membranous expression of ectodomain isoforms of the epidermal
growth factor receptor predicts outcome after chemoradiotherapy of
lymph node-negative cervical cancer. Clin Cancer Res. 17:5501–5512.
2011. View Article : Google Scholar
|
|
41
|
Iida K, Nakayama K, Rahman MT, et al: EGFR
gene amplification is related to adverse clinical outcomes in
cervical squamous cell carcinoma, making the EGFR pathway a novel
therapeutic target. Br J Cancer. 105:420–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schrevel M, Karim R, ter Haar NT, et al:
CXCR7 expression is associated with disease-free and
disease-specific survival in cervical cancer patients. Br J Cancer.
106:1520–1525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Monk BJ, Mas Lopez L, Zarba JJ, et al:
Phase II, open-label study of pazopanib or lapatinib monotherapy
compared with pazopanib plus lapatinib combination therapy in
patients with advanced and recurrent cervical cancer. J Clin Oncol.
28:3562–3569. 2010. View Article : Google Scholar
|
|
44
|
Costa S, Terzano P, Bovicelli A, et al:
CD44 isoform 6 (CD44v6) is a prognostic indicator of the response
to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol.
80:67–73. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chung HH, Kim MK, Kim JW, et al: XRCC1
R399Q polymorphism is associated with response to platinum-based
neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol.
103:1031–1037. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Faried LS, Faried A, Kanuma T, et al:
Predictive and prognostic role of activated mammalian target of
rapamycin in cervical cancer treated with cisplatin-based
neoadjuvant chemotherapy. Oncol Rep. 16:57–63. 2006.PubMed/NCBI
|
|
47
|
Gupta RA and Dubois RN: Colorectal cancer
prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev
Cancer. 1:11–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang F, Engebretson SP, Morton RS,
Cavanaugh PF Jr, Subbaramaiah K and Dannenberg AJ: The
overexpression of cyclo-oxygenase-2 in chronic periodontitis. J Am
Dent Assoc. 134:861–867. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Katori M and Majima M: Cyclooxygenase-2:
its rich diversity of roles and possible application of its
selective inhibitors. Inflamm Res. 49:367–392. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kulkarni S, Rader JS, Zhang F, et al:
Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin
Cancer Res. 7:429–434. 2001.PubMed/NCBI
|
|
51
|
Raju U, Ariga H, Dittmann K, Nakata E, Ang
KK and Milas L: Inhibition of DNA repair as a mechanism of enhanced
radioresponse of head and neck carcinoma cells by a selective
cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol
Phys. 63:520–528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xia S, Zhao Y, Yu S and Zhang M: Activated
PI3K/Akt/COX-2 pathway induces resistance to radiation in human
cervical cancer HeLa cells. Cancer Biother Radiopharm. 25:317–323.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang AH, Tian XY, Yu JJ, Mi JQ, Liu H and
Wang RF: Celecoxib radiosensitizes the human cervical cancer HeLa
cell line via a mechanism dependent on reduced cyclo-oxygenase-2
and vascular endothelial growth factor C expression. J Int Med Res.
40:56–66. 2012. View Article : Google Scholar
|
|
54
|
Ferrandina G, Ranelletti FO, Legge F, et
al: Prognostic role of the ratio between cyclooxygenase-2 in tumor
and stroma compartments in cervical cancer. Clin Cancer Res.
10:3117–3123. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim YB, Kim GE, Pyo HR, et al:
Differential cyclooxygenase-2 expression in squamous cell carcinoma
and adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol
Phys. 60:822–829. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kim GE, Kim YB, Cho NH, et al: Synchronous
coexpression of epidermal growth factor receptor and
cyclooxygenase-2 in carcinomas of the uterine cervix: a potential
predictor of poor survival. Clin Cancer Res. 10:1366–1374. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Suzuki M, Tsukagoshi S, Saga Y, Ohwada M
and Sato I: Enhanced expression of thymidylate synthase may be of
prognostic importance in advanced cervical cancer. Oncology.
57:50–54. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kawanaka T, Kubo A, Ikushima H, Sano T,
Takegawa Y and Nishitani H: Prognostic significance of HIF-2alpha
expression on tumor infiltrating macrophages in patients with
uterine cervical cancer undergoing radiotherapy. J Med Invest.
55:78–86. 2008. View Article : Google Scholar
|
|
59
|
Blancher C, Moore JW, Talks KL, Houlbrook
S and Harris AL: Relationship of hypoxia-inducible factor
(HIF)-1alpha and HIF-2alpha expression to vascular endothelial
growth factor induction and hypoxia survival in human breast cancer
cell lines. Cancer Res. 60:7106–7113. 2000.
|
|
60
|
Ziemer LS, Koch CJ, Maity A, Magarelli DP,
Horan AM and Evans SM: Hypoxia and VEGF mRNA expression in human
tumors. Neoplasia. 3:500–508. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Vaupel P, Kelleher DK and Höckel M: Oxygen
status of malignant tumors: pathogenesis of hypoxia and
significance for tumor therapy. Semin Oncol. 28(Suppl 8): 29–35.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Girinski T, Pejovic-Lenfant MH, Bourhis J,
et al: Prognostic value of hemoglobin concentrations and blood
transfusions in advanced carcinoma of the cervix treated by
radiation therapy: results of a retrospective study of 386
patients. Int J Radiat Oncol Biol Phys. 16:37–42. 1989. View Article : Google Scholar
|
|
63
|
Thomas G: The effect of hemoglobin level
on radiotherapy outcomes: the Canadian experience. Semin Oncol.
28(Suppl 8): 60–65. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hernandez E, Donohue KA, Anderson LL,
Heller PB and Stehman FB: The significance of thrombocytosis in
patients with locally advanced cervical carcinoma: a Gynecologic
Oncology Group study. Gynecol Oncol. 78:137–142. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kato H and Torigoe T: Radioimmunoassay for
tumor antigen of human cervical squamous cell carcinoma. Cancer.
40:1621–1628. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kato H, Morioka H, Tsutsui H, Aramaki S
and Torigoe T: Value of tumor-antigen (TA-4) of squamous cell
carcinoma in predicting the extent of cervical cancer. Cancer.
50:1294–1296. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Maruo T, Shibata K, Kimura A, Hoshina M
and Mochizuki M: Tumor-associated antigen, TA-4, in the monitoring
of the effects of therapy for squamous cell carcinoma of the
uterine cervix. Serial determinations and tissue localization.
Cancer. 56:302–308. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bolger BS, Dabbas M, Lopes A and Monaghan
JM: Prognostic value of preoperative squamous cell carcinoma
antigen level in patients surgically treated for cervical
carcinoma. Gynecol Oncol. 65:309–313. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Takeshima N, Hirai Y, Katase K, Yano K,
Yamauchi K and Hasumi K: The value of squamous cell carcinoma
antigen as a predictor of nodal metastasis in cervical cancer.
Gynecol Oncol. 68:263–266. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Puthucode-Easwaran S, Naik R, Athavale R,
et al: Comparison of pre-treatment CYFRA 21–1 and SCC-Antigen assay
in primary cervical carcinoma - a preliminary report. J Obstet
Gynaecol. 25:486–488. 2005.
|
|
71
|
Duk JM, de Bruijn HW, Groenier KH, et al:
Cancer of the uterine cervix: sensitivity and specificity of serum
squamous cell carcinoma antigen determinations. Gynecol Oncol.
39:186–194. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yamakawa H, Konno R, Enomoto A, et al:
Prognostic factors of uterine cervical cancer. Gan To Kagaku Ryoho.
33:2002–2007. 2006.(In Japanese).
|
|
73
|
te Velde ER, Persijn JP, Ballieux RE and
Faber J: Carcinoembryonic antigen serum levels in patients with
squamous cell carcinoma of the uterine cervix: clinical
significance. Cancer. 49:1866–1873. 1982.
|
|
74
|
Hori T, Ichimura H, Minamihisamatsu M, et
al: Chromosomal insertion and amplification of human papillomavirus
16 DNA sequences in a cell line of argyrophil small cell carcinoma
of the uterine cervix. Jpn J Cancer Res. 82:371–375. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Couturier J, Sastre-Garau X,
Schneider-Maunoury S, Labib A and Orth G: Integration of
papillomavirus DNA near myc genes in genital carcinomas and its
consequences for proto-oncogene expression. J Virol. 65:4534–4538.
1991.PubMed/NCBI
|
|
76
|
Iwasaka T, Yokoyama M, Oh-uchida M, et al:
Detection of human papillomavirus genome and analysis of expression
of c-myc and Ha-ras oncogenes in invasive cervical carcinomas.
Gynecol Oncol. 46:298–303. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Pinion SB, Kennedy JH, Miller RW and
MacLean AB: Oncogene expression in cervical intraepithelial
neoplasia and invasive cancer of cervix. Lancet. 337:819–820. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Riou G, Lê MG, Favre M, Jeannel D, Bourhis
J and Orth G: Human papillomavirus-negative status and c-myc gene
overexpression: independent prognostic indicators of distant
metastasis for early-stage invasive cervical cancers. J Natl Cancer
Inst. 84:1525–1526. 1992. View Article : Google Scholar
|
|
79
|
Ohta M, Inoue H, Cotticelli MG, et al: The
FHIT gene, spanning the chromosome 3p14.2 fragile site and renal
carcinoma-associated t(3;8) breakpoint, is abnormal in digestive
tract cancers. Cell. 84:587–597. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Machida S, Ohwada M, Saga Y and Suzuki M:
Abnormal fragile histidine triad expression in advanced cervical
cancer and evaluation of its utility as a prognostic factor.
Oncology. 65:89–93. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liao CJ, Wu TI, Huang YH, et al:
Glucose-regulated protein 58 modulates cell invasiveness and serves
as a prognostic marker for cervical cancer. Cancer Sci.
102:2255–2263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Togami S, Nomoto M, Higashi M, et al:
Expression of mucin antigens (MUC1 and MUC16) as a prognostic
factor for mucinous adenocarcinoma of the uterine cervix. J Obstet
Gynaecol Res. 36:588–597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Hebbar V, Damera G and Sachdev GP:
Differential expression of MUC genes in endometrial and cervical
tissues and tumors. BMC Cancer. 5:1242005. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kodama J, Yoshinouchi M, Seki N, Hongo A,
Miyagi Y and Kudo T: Angiogenesis and platelet-derived endothelial
cell growth factor/thymidine phosphorylase expression in cervical
cancer. Int J Oncol. 15:149–154. 1999.PubMed/NCBI
|
|
85
|
Jussila L and Alitalo K: Vascular growth
factors and lymphangiogenesis. Physiol Rev. 82:673–700.
2002.PubMed/NCBI
|
|
86
|
Hashimoto I, Kodama J, Seki N, et al:
Vascular endothelial growth factor-C expression and its
relationship to pelvic lymph node status in invasive cervical
cancer. Br J Cancer. 85:93–97. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ishikawa F, Miyazono K, Hellman U, et al:
Identification of angiogenic activity and the cloning and
expression of platelet-derived endothelial cell growth factor.
Nature. 338:557–562. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Fujimoto J, Sakaguchi H, Hirose R, Wen H
and Tamaya T: Clinical implication of expression of
platelet-derived endothelial cell growth factor (PD-ECGF) in
metastatic lesions of uterine cervical cancers. Cancer Res.
59:3041–3044. 1999.PubMed/NCBI
|
|
89
|
Jiang T, Huang L, Wang S and Zhang S:
Clinical significance of serum Dkk-3 in patients with gynecological
cancer. J Obstet Gynaecol Res. 36:769–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Hanprasertpong J, Tungsinmunkong K,
Chichareon S, et al: Correlation of p53 and Ki-67 (MIB-1)
expressions with clinicopathological features and prognosis of
early stage cervical squamous cell carcinomas. J Obstet Gynaecol
Res. 36:572–580. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Shirendeb U, Hishikawa Y, Moriyama S, et
al: Human papillomavirus infection and its possible correlation
with p63 expression in cervical cancer in Japan, Mongolia, and
Myanmar. Acta Histochem Cytochem. 42:181–190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Cimpean AM, Saptefrati L, Ceausu R and
Raica M: Characterization of endoglin and Ki-67 expression in
endothelial cells from benign and malignant lesions of the uterine
cervix. Pathol Int. 59:695–700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhang JM, Hashimoto M, Kawai K, et al:
CD109 expression in squamous cell carcinoma of the uterine cervix.
Pathol Int. 55:165–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
